您好,欢迎访问中山大学肿瘤防治中心官方网站!
内部网 职工邮箱 图书馆 OA系统 医生门户 English
院士风采 首席专家 临床专家 科研学者 客座教授 人才名录
首页
  • 谢方云

    职务:
    职称:教授,主任医师,博士生导师。
    专长:擅长头颈部肿瘤放射治疗,特别是鼻咽癌的精确调强放疗和综合治疗。

      谢方云
      职称:教授、主任医师、博士生导师
      专长:头颈部肿瘤,尤其是鼻咽癌的临床诊断、放射治疗及综合治疗

    一、基本情况
      职称:教授、主任医师、博士生导师
      专业特长:头颈肿瘤,尤其是鼻咽癌的临床诊断、放射治疗及综合治疗
      专家门诊时间:周二下午、周三上午
      主攻方向如下:①鼻咽癌的调强放射治疗、图像引导放射治疗及自适应放疗;②鼻咽癌调强放射治疗及个体化精准治疗;③头颈部肿瘤的调强放射治疗及综合治疗

    二、学习及工作经历
      1980.09-1985.07 湖南医学院 临床医学 本科 获学士学位
      1990.09-1994.07 中山医科大学 肿瘤学 获硕士学位
      1985.07-1993.08 中山大学肿瘤防治中心 放疗科 住院医师
      1993.08-2002.08 中山大学肿瘤防治中心 放疗科 主治医师
      2002.08-2011.12 中山大学肿瘤防治中心 放疗科 副主任医师
      2011.12-2016.12 中山大学肿瘤防治中心 放疗科 主任医师
      2016.12-至今 中山大学肿瘤防治中心 放疗科 教授、主任医师

    三、学术兼职
      广东省医师协会放射肿瘤分会 副主任委员

      谢方云
      职称:教授、主任医师、博士生导师
      专长:头颈部肿瘤,尤其是鼻咽癌的临床诊断、放射治疗及综合治疗

    一、基本情况
      职称:教授、主任医师、博士生导师
      专业特长:头颈肿瘤,尤其是鼻咽癌的临床诊断、放射治疗及综合治疗
      专家门诊时间:周二下午、周三上午
      主攻方向如下:①鼻咽癌的调强放射治疗、图像引导放射治疗及自适应放疗;②鼻咽癌调强放射治疗及个体化精准治疗;③头颈部肿瘤的调强放射治疗及综合治疗

    二、学习及工作经历
      1980.09-1985.07  湖南医学院   临床医学   本科   获学士学位
      1990.09-1994.07  中山医科大学   肿瘤学  获硕士学位
      1985.07-1993.08  中山大学肿瘤防治中心   放疗科  住院医师
      1993.08-2002.08  中山大学肿瘤防治中心   放疗科  主治医师
      2002.08-2011.12  中山大学肿瘤防治中心   放疗科  副主任医师
      2011.12-2016.12  中山大学肿瘤防治中心   放疗科  主任医师
      2016.12-至今     中山大学肿瘤防治中心   放疗科  教授、主任医师

    三、学术兼职
      广东省医师协会放射肿瘤分会   副主任委员

     四、主持科研项目
    ①国家自然科学基金重点项目 cdh1(FZR1)磷酸化新点被调控的机理,对功能的影响及其意义(2009-2013年,第2负责人)
    ②国家自然科学基金面上项目  Fli-1靶向上调VEGF-C促进鼻咽癌转移的分子机制和临床意义研究(2017-2020年 第1负责人)
    ③广东省自然科学基金 Fli-1靶向调控VEGF-C促进鼻咽癌生长和转移的研究(2017-2020,第1负责人)
    ④广东省科学技术厅 多西他赛加顺铂(TP)对比单药顺铂(DDP)的同期化疗联合调强放疗治疗高危局部区域晚期鼻咽癌的随机对照II期临床研究(2016-2018年,第1负责人)
    ⑤中山大学5010项目 调强放疗加或不加同期化疗治疗II期鼻咽癌的非劣效性、随机对照、多中心III期临床研究(2015-2025年,第1负责人)

    五、第一及或通讯作者发表SCI文章
    1. Xiang-Bo Wan, Rou Jiang, Fang-Yun Xie (Co-first authors), Zhen-Yu Qi, Ai-Ju Li, Wei-Jun Ye, Yi-Jun Hua, Yu-Liang Zhu, Xiong Zou, Ling Gao, Hai-Qiang Mai, Xiang Guo, Ming-Huang Hong, Ming Yuan Che. Endoscope—guided interstitial intensity-modulated brachytherapy and intracavitary brachytherapy as boost radiation for primary early T stage nasopharyngeal carcinoma. PLoS One 2014;9;e90048.(IF 2.806)
    2. Xiao-Bin Lv, Fangyun Xie (Co-first authors), Kaishun Hu, Yuanzhong Wu, Lin-Lin Cao, Xia Han, Yi Sang, Yi-Xin Zeng, and Tiebang Kang. Damaged DNA-binding protein 1(DDB1) interacts with Cdhl and modulates the function of APC/CCdhl. J Biol Chem 2010; 285:18234-18240.(IF 4.125)
    3. Pu-Yun OuYang, MD, Lu-Ning Zhang, MD, Jie Tang, MD, Xiao-Wen Lan, MD, Yao Xiao, MD, Yuan-Hong Gao, MD, and Fang-Yun Xie, Md. Evaluation of Body Mass Index and Survival of Nasopharyngeal Carcinoma by Propensity-Matched Analysis: An Observational Case-Control Study. Medicine (Baltimore)2016;95:e2380(IF 1.803)
    4. Lu-Ning Zhang, Yuan-Hong Gao, Xiao-Wen Lan, Jie Tang, Zhen Su, Jun Ma, Wuguo Deng,Pu-Yun OuYang, Fang-Yun Xie. Propensity score matching analysis of cisplatin-based concurrent chemotheraoy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotheraphy era. Oncotarget 2015;6:44019-44029(IF 5.168)
    5. P-Y OuYang, L-N Zhang, X-W Lan, C Xie, W-W Zhang, Q-X Wang, Z Su, J Tang and F-Y Xie. The significant survival advantage of female sex in nasopharyngeal carcinoma:a propensity-matched analysis. Br J Cancer 2015;112:1554-1561(IF 6.176)
    6. Lu-Ning Zhang, Jie Tang, Xiao-Wen Lan, Pu-Yun OuYang, Fang-Yun Xie. Pretreatment anemia and survival in nasopharyngeal carcinoma. Tumour Biol 2015(IF 3.65)
    7. Zhen Su, Yan-Ping Mao, Jie Tang, Xiao-Wen Lan, Pu-Yun Ouyang, Fang-Yun Xie. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT:a retrospective study. Tumour Biol 2015(IF 3.65)
    8. Lu-Ning Zhang, Yuan-Hong Gao, Xiao-Wen Lan, Jie Tang, Pu-Yun OuYang, Fang-Yun Xie. Effect of taxanes-based induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A large scale propensity-matched study. Oral Oncol 2015;51:950-956(IF 4.794)
    9. Zhen Su, Yan-Ping Mao, Pu-Yun OuYang, Jie Tang, Xiao-Wen Lan and Fang-Yun Xie. Leucopenia and treatment efficacy in advanced nasopharyngeal carcinoma. BMC Cancer 2015;15:429(IF 3.288)
    10. Zhen Su, Yan-Ping Mao, Pu-Yun OuYang, Jie Tang, Fang-Yun Xie. Initial Hyperleukocytosis and Neutrophilia in Nasopharyngeal Carcinoma: Incidence and Prognostic Impact. PLoS One2015;10:e0136752(IF 2.806)
    11. Xue-Xia Liang, Qun Li, Zhen Su, Xiao-Wen Lan, Pu-Yun OuYang, Yan-Ping Mao, Ding-Bo Shi, Wu-Guo Deng, Zhi-Bin Cheng, Si-Yang Wang, Fang-Yun Xie. Significant prognostic impact of chemoradiatherapy-induced hemoglobin decrease on treatment outcomes of nasopharyngeal carcinoma. J Cancer 2015;6;:502-510(IF 2.916)
    12. Pu-Yun OuYang, Zhen Su, Jie Tang, Xiao-Wen Lan, Yan-Ping Mao,Wuguo Deng, Fang-Yun Xie. Diabetes,Prediabetes and the Survival of Nasopharyngeal Carcinoma:A Study of 5,860 Patients. PLoS One2014;9:e111073(IF 2.806)
    13. Xuexia Liang, Dingbo Shi, Jingping Yun, Yanping Mao,Puyun Ouyang, Zhen Su, Jia Fu, Jinghui Hou, Wuguo Deng and Fangyun Xie. Friend leukemia virus integration 1 expression has prognostic significance in nasopharyngeal carcinoma. Transl Oncol 2014;7:493-502(IF 3.025)
    14.P.Y.OuYang,C.Xie,Y.P.Mao,Y.Zhang,X.X.Liang,Z.Su,Q.Liu&F.Y.Xie. Significant efficacies of neoadjuvant and adjuvant chemotherapy for nasopharyngeal carcinoma by meta-analysis of published literature-based randomized, controlled trials. Ann Oncol 2013;24:2136-2146(IF 11.855)
    15. P-Y OuYang, Z Su, Y-P Mao, Q Liu and F-Y Xie. Prognostic value of ABO blood group in southern Chinese patients with established nasopharyngeal carcinoma. Br J Cancer 2013;109:2462-2466(IF 6.176)
    16. Pu-Yun OuYang, Zhen Su, Yan-Ping Mao, Xue-Xia Liang, Qing Liu, Wu-Guo Deng, and Fang-Yun Xie. Prognostic impact of family history in southern Chinese patients with undifferentiated nasopharyngeal carcinoma. Br J Cancer 2013;109:788-794(IF 6.176)
    17. P-Y OuYang, Z Su,X-H Ma, Y-P Mao, M-Z Liu and F-Y Xie. Comparison of TNM staging systems for nasopharyngeal carcinoma, and proposal of a new staging system. Br J Cancer 2013;109:2987-29979(IF 6.176)
    18. P-Y OuYang, Z Su, Y-P Mao, X-X Liang, Q Liu and F-Y Xie. Prognostic impact of cigarette smoking on the survival of patients with established nasopharyngeal carcinoma.Cancer Epidemiol Biomarkers Prev 2013;22:2285-2294(IF 6.176)
    19. Pu-Yun OuYang, Zhen Su, Yan-Ping Mao, Wuguo Deng, Fang-Yun Xie. Combination of EGFR-TKIs and Chemotherapy as First-Line Therapy for Advanced NSCLC:A Meta-Analysis. PLoS One2018;8:e79000(IF 2.806)
    20. Xin Wang, Yi Liang, Qiong Chen, Hui-Min Xu, Nan Ge,Rong-Zhen Luo, Jian-Yong Shao, Zhi-Wei He, Yi-Xin Zeng, Tiebang Kang, Jing-Ping Yun &Fangyun Xie. Prognostic significance of SOX2 exoression in nasopharyngeal carcinoma. Cancer Invest 2012;30:79-85(IF 2.007)
    21. Hui-Min Xu, Yi Liang, Qiong Chen, Qi-Nian Wu, Yun-Miao Guo, Guo-Ping Shen, Ru-Hua Zhang, Zhi-Wei He, Yi-Xin Zeng, Fang-Yun Xie, and Tie-Bang Kang. Correlation of Skp2 overexpression to prognosis of patients with nasopharyngeal carcinoma from South China. Chin J Cancer2011;30:204-212(IF 4.111)
    22. Pu-Yun OuYang, Dingbo Shi, Rui Sun, Yu-Jia Zhu, Yao Xiao,Lu-Ning Zhang, Xu-Hui Zhang, Ze-Ying Chen, Xiao-Wen Lan, Jie Tang, Yuan-Hong Gao, Jun Ma, Wuguo Deng, Fang-Yun Xie. Effect of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy alone in nasopharyngeal carcinoma. Oncotarget. 2016 Apr 4.(IF 5.168)
    23. Zhen Su, Yan-Ping Mao, Jie Tang, Xiao-Wen Lan, Pu-Yun OuYang, Fang-Yun Xie. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study. Tumor Biol. 2016 Apr;37(4):4429-38(IF 3.65)
    24. Pu-Yun OuYang, Zhuo-Fei Bi, Lu-Ning Zhang, Kai-Yun You, Yao Xiao, Xiao-Wen Lan, Jie Tang, Xi-Cheng Wang, Wuguo Deng and Fang-Yun Xie. Outcomes of Induction Chemotherapy Plus Intensity-Modulated Radiotherapy (IMRT) Versus IMRT Plus Concurrent Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Study. Transl Oncol. 2016; 9(4):329-335.(IF 3.025)
    25. Xiao-Wen Lan, Xue-Bin Zou, Yao Xiao, Jie Tang, Pu-Yun OuYang, Zhen Su, Fang-Yun Xie. Retrospective Analysis of the Survival Benefit of Induction Chemotherapy in Stage Iva-b Nasopharyngeal Carcinoma:Plos One.2016;11(8):e0160758.(IF 2.806)
    26. Lei Chen, Chao-Su Hu, Xiao-Zhong Chen, Guo-Qing Hu, Zhi-Bin Cheng, Yan Sun, Wei-Xiong Li, Yuan-Yuan Chen, Fang-Yun Xie, Shao-Bo Liang, Yong Chen, Ting-Ting Xu, Bin Li, Guo-Xian Long, Si-Yang Wang, Bao-Min Zheng, Ying Guo, Ying Sun, Yan-Ping Mao, Ling-Long Tang, Yu-Ming Chen, Meng-Zhong Liu, Jun Ma.Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomiased controlled trial. Lancet Oncol2012;13:163-71(IF 33.9)
    27. Ying Sun, Wen-Fei Li, Nian-Yong Chen, Ning Zhang, Guo-Qing Hu, Fang-Yun Xie (Co-first authors), Yan Sun, Xiao-Zhong Chen, Jin-Gao Li, Xiao-Dong Zhu. Chao-Su Hu, Xiang-Ying Xu, Yuan-Yuan Chen, Wei-Han Hu, Ling Guo, Hao-Yuan Mo, Lei Chen, Yan-Ping Mao, Rui-Sun, Ping Ai, Shao-Bo Liang, Guo-Xian Long, Bao-Min Zhang, Xing-Lai Feng, Xiao-Chang Gong, Ling Li, Chun-Ying Shen, Jian-Yu Xu, Ying Guo, Yu-Ming Chen, Dan Zhang, Li Lin, Ling-Long Tang, Meng-Zhong Liu, Jun Ma. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicenter, randomized controlled trial. Lancet Oncol 2016:1470-2045(IF 33.9)
    28. Xiao-Wen Lan, Yao Xiao, Xue-Bin Zou, Pu-Yun OuYang, Fang-Yun Xie. Outcomes of adding induction chemotherapy to concurrent chemoradiotherapy for stage T3N0-1 nasopharyngeal carcinoma: a propensity-matched study. OncoTargets and Therapy 2017:10 3853-3860(IF 2.3184)
    29. Pu-Yun OuYang, Yao Xiao, Kai-Yun You, Lu-Ning Zhang, Xiao-Wen Lan, Xiao-Min Zhang, Fang-Yun Xie. Validation and comparison of the 7th and 8th edition of AJCC staging systems for non-metastatic nasopharyngeal carcinoma, and proposed staging systems from Hong Kong, Guangzhou, and Guangxi. Oral Oncol 2017; 72: 65-72. (IF 4.794)
    30. Pu-Yun OuYang, Lu-Ning Zhang, Yao Xiao, Xiao-Wen Lan, Xiao-Min Zhang, Jun Ma, Fang-Yun Xie. Validation of published nomograms and accordingly individualized induction chemotherapy in nasopharyngeal carcinoma. Oral Oncol 2017;67:37-45.(IF 4.794)

    六、获得奖项
    1. 国家科技进步二等奖  鼻咽癌诊疗关键策略研究与应用(2015年,第7完成人)
    2. 中华医学科技奖一等奖  鼻咽癌个体化治疗研究与应用(2014年,第7完成人)
    3. 高等学校科学技术进步将一等奖  鼻咽癌个体化治疗研究与应用(2015年,第7完成人)
    4. 广东省科学技术奖励一等奖  鼻咽癌个体化治疗研究与应用(2015年,第7完成人)

     
    更新时间:2017年11月2日

访客通道
员工通道
关注肿瘤医院
留言建议 ×